Transaction DateRecipientSharesTypePriceValue
18th September 2020William Jr Lehmann20,000Open or private sale$2.04$40,764.00
17th September 2020Bokkelen Gil Van26,656Payment by withholding$2.06$54,911.36
17th September 2020William Jr Lehmann13,528Payment by withholding$2.06$27,867.68
17th September 2020Laura K Campbell8,943Payment by withholding$2.06$18,422.58
17th September 2020John J Harrington15,947Payment by withholding$2.06$32,850.82
16th September 2020John J Harrington5,000Open or private sale$2.15$10,761.00
15th September 2020John J Harrington5,000Open or private sale$2.21$11,032.50
28th July 2020Kenneth H Traub27,000Grant/award etc.$0.00
24th June 2020Kenneth H Traub20,000Open or private purchase$2.24$44,800.00
24th June 2020Kenneth H Traub20,000Open or private purchase$2.21$44,200.00
Athersys logo

Athersys, Inc. engages in the discovery and development of therapies designed to extend and enhance to quality of human life. It offers MultiStem as its stem cell product which provides biological potency and therapeutic effects. The company was founded by John J. Harrington and Gil van Bokkelen on October 24, 1995.

Ticker: ATHX
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1368148
Employees: 83
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Cash at Carrying Value: $81 M (0%)
Assets, Current: $82 M (120%)
Property, Plant and Equipment, Net: $3 M (9%)
Assets: $86 M (107%)
Accrued Liabilities, Current: $2 M (120%)
Liabilities, Current: $17 M (31%)
Other Liabilities, Noncurrent: $48 Th (-78%)
Common Stock, Value, Issued: $197 Th (23%)
Common Stock, Shares, Issued: $197 M (23%)
Additional Paid in Capital, Common Stock: $516 M (16%)
Retained Earnings (Accumulated Deficit): $452 M (0%)
Stockholders' Equity (Parent): $64 M (0%)
Liabilities and Equity: $86 M (107%)
Research and Development: $14 M (-46%)
General and Administrative Expenses: $4 M (-43%)
Operating Income/Loss: $18 M (-46%)